Dr. Südhof argues some major trials don’t possess the necessary “underlying science,” reflecting a “moonshot in the dark.” He suggests the industry change the methods for biomedical research and drug development.
The first step involves actually understanding the diseases for which researchers seek treatments. Dr. Südhof comments without grasping a disease’s mechanisms, researchers will have little luck finding a treatment.
He notes the majority of genes possess various functions, and if researchers are unaware of all those tasks, they will likely target the incorrect ones for therapy.
Moving forward, Dr. Südhof encourages funds and time to go toward basic research of diseases. With this foundation, researchers should then move forward into clinical trials equipped with a solid plan.
More articles on practice management:
UnitedHealthcare partners with Baylor on bundled payment pilot: 6 key points
AMA: 6 top issues for physicians in 2017
Baptist Health expenditures on total joints without complications drop 20.8% after bundled payments — 8 key points
